Domestic pharmaceutical companies are catching up multinational ones in the KRW 600 billion domestic hyperlipidemia treatment market

In the hyperlipidemia treatment market, multinational and domestic pharmaceutical companies are having fierce competitions.

Last year, the size of the domestic hyperlipidemia treatment market was KRW 600 million (80% in the market are statin-type drugs), and the top 10 pharmaceutical companies are occupying more than 70% of the market (KRW 430 billion).

The atmosphere in the market is that do...